查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371920

噬菌体疗法的全球市场，到 2030 年的市场预测：按产品、类型、目标细菌、适应症、给药途径、给药配销通路、用途、最终用户、地区进行全球分析

Bacteriophage Therapy Market Forecasts to 2030 - Global Analysis By Product, Type, Targeted Bacteria, Disease Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球噬菌体治疗市场规模为 4,659 万美元，预计 2030 年将达到 8,090 万美元，年复合成长率为 8.2%。

噬菌体是仅攻击和杀死细菌的病毒。噬菌体是最常见的生物体，可以对抗和消灭具有多重抗药性的细菌。当所有其他抗生素都失效时，噬菌体可以消除引起感染疾病的细菌，使医护人员得以挽救生命。此外，噬菌体正在被研究作为抗生素的替代疗法。这种治疗方法使用病毒将遗传物质注入细菌中，使它们能够利用宿主的机器进行繁殖。

根据美国疾病管制与预防中心 (CDC) 的数据，欧洲每年约有 33,000 人受到抗生素抗药性细菌感染疾病的影响。预计全球抗生素抗药性将增加，对噬菌体产生巨大需求。

抗生素抗药性增加

在人类医学和农业中过度使用抗生素会产生严重后果，包括抗生素抗药性增加。这种令人震惊的趋势导致了抗生素抗药性超级细菌的出现，并迫切需要噬菌体疗法等替代疗法。此外，噬菌体是天然存在的病毒，能够靶向并消灭细菌，使其成为对抗这些抗药性病原体的有前途的武器。研究人员正在研究如何使用噬菌体混合物和专门设计的噬菌体有效地瞄准和消除这些顽固的细菌菌株。

临床资料不足和法规障碍

要让法规相信噬菌体疗法的安全性和有效性是很困难的。这是因为能够提供足够临床证据的大规模随机对照试验并不多。然而，新治疗方法的法规环境非常严格，需要大量的临床资料，这使得获得产品核准既耗时又昂贵。在克服这些挑战的同时，开发人员还必须解决临床试验中使用的噬菌体製剂的一致性和品质问题。

研发投资

快速增加的研发成本推动了噬菌体疗法的创新。噬菌体工程、噬菌体文库的创建以及噬菌体疗法与免疫疗法和抗生素等其他治疗方法的结合都是活跃的研究主题。此外，这种动态环境不仅使治疗工具箱多样化，而且促进了对噬菌体生物学及其临床应用的深入理解。

法规问题和缺乏可靠的临床资料

缺乏大规模、一流的临床资料是噬菌体治疗市场的最大威胁之一。由于噬菌体疗法的临床试验相对较少，法规可能会推迟核准并增加开发成本。此外，法规机构核准新治疗方法需要强有力的临床证据。对于开发商来说，适应新治疗方法的法规环境可能既困难又耗时。

COVID-19 的影响

噬菌体治疗市场受到了 COVID-19大流行的各种影响。虽然噬菌体和其他替代疗法由于人们对感染疾病和抗生素抗药性的日益关注而受到更多关注，但这场大流行也将更多的资源、注意力和研究工作集中在了 COVID-19 上。供应链问题推迟了噬菌体疗法的临床试验和研究，并导致生产中断。儘管如此，这场大流行病还是引起了人们对多种治疗选择的需求的关注，特别是医疗机构中持续存在的细菌威胁，以及在大流行后时代加速采用噬菌体疗法治疗抗生素抗药性感染疾病的潜力。是。

在预测期内，尿道感染领域预计将是最大的。

尿道感染（UTI）领域占据噬菌体治疗市场的最大份额。每年，数百万人患有尿道结石，这是最常见的细菌感染疾病之一。此外，由于导致尿道结石的抗生素抗药性菌株数量不断增加，噬菌体疗法已成为有前途的选择。噬菌体疗法可有效针对特定的泌尿道致病细菌，尿道结石。尿道结石的复发性和抗生素在预防復发方面的限制进一步增加了基于噬菌体的治疗方法在该市场的市场潜力。

预计抗生素发现领域在预测期内年复合成长率最高

在噬菌体治疗市场，抗菌药物的发现正以最高的年复合成长率成长。世界各地对抗生素抗药性的担忧日益增加，导致寻找新抗菌药物的资金和研究不断增加。噬菌体靶向并消灭抗生素抗药性细菌的能力引起了药物研发配合措施的极大兴趣。此外，不断探索噬菌体发现和创造新抗菌药物的潜力是该市场快速成长的关键驱动力，是解决严重的抗药性感染疾病问题的迫切需求的解决方案。

占比最大的地区：

预计北美地区将拥有噬菌体疗法最高的市场占有率。造成这一优势的因素有很多，包括强大的医疗基础设施、抗生素抗药性细菌引起的感染疾病发生率高、研发方面的大量投资以及支持性的法规环境。北美由于该地区生物技术和製药行业的蓬勃发展以及噬菌体疗法在临床实践中的使用不断增加而引领市场。此外，透过学术机构、製药公司和政府机构之间的合作，噬菌体疗法在北美迅速扩张，目前占据最大的市场占有率。

复合年复合成长率最高的地区

在全球噬菌体治疗市场中，亚太地区的年复合成长率最高。这种快速扩张是多种要素共同作用的结果，包括抗生素抗药性感染疾病的流行、医疗保健行业的扩张以及公众对噬菌体疗法潜在优势的认识不断提高。亚太地区正在大力投资研发，重点是建立高效的生产技术和扩大临床应用。此外，当地学术机构、外国製药公司和当地生物技术公司之间的合作正在促进创新并扩大市场。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球噬菌体治疗市场：按产品

  • 噬菌体益生菌
  • 噬菌体疗法
  • 其他产品

第6章全球噬菌体治疗市场：依类型

  • 赫里尼克
  • 溶原性
  • 其他类型

第7章全球噬菌体治疗市场：依目标细菌

  • 大肠桿菌
  • 金黄色葡萄球菌
  • 链球菌
  • 铜绿假单胞菌
  • 沙门氏菌
  • 其他目标细菌

第8章全球噬菌体治疗市场：依疾病适应症

  • 尿道感染
  • 慢性中耳炎
  • 拔牙
  • 慢性溃疡性大肠炎
  • 骨感染疾病
  • 伤口和皮肤感染疾病
  • 囊性纤维化
  • 其他疾病适应症

第9章全球噬菌体治疗市场：依给药途径

  • 口服
  • 局部的
  • 胃肠外的

第10章全球噬菌体治疗市场：依配销通路

  • 医院药房
  • 零售药房
  • 网路药房

第11章全球噬菌体治疗市场：依用途

  • 皮肤感染疾病的治疗
  • 消化内科
  • 预防伤口
  • 呼吸道感染疾病的治疗
  • 泌尿生殖感染疾病的治疗
  • 诊断
  • 抗生素药物药物研发
  • 老兵专用医药
  • 其他用途

第12章全球噬菌体治疗市场：依最终用户分类

  • 医院/诊所
  • 学术研究组织/机构
  • 其他最终用户

第13章全球噬菌体治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第14章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第15章公司简介

  • InnoPhage Ltd
  • Eliava Biopreparations Ltd.
  • Adaptive Phage Therapeutics, Inc
  • Nextbiotics
  • Armata Pharmaceuticals Inc.
  • Enbiotix Inc.
  • Eligo Bioscience SA
  • BiomX Ltd.
  • Phagomed Biopharma GmbH
  • Intodeworld Inc.
  • Phi Therapeutics
  • ContraFect Corporation
  • Locus Biosciences Inc.
  • Intralytix Inc.
  • PhagePro Inc.
  • Pherecydes Pharma
  • TechnoPhage SA
Product Code: SMRC23977

According to Stratistics MRC, the Global Bacteriophage Therapy Market is accounted for $46.59 million in 2023 and is expected to reach $80.90 million by 2030 growing at a CAGR of 8.2% during the forecast period. Bacteriophages are viruses that only attack and kill bacteria. They are among the most prevalent biological organisms capable of battling and eliminating bacteria with multiple drug resistances. Phages can eliminate the bacteria causing an infection when all other antibiotics have failed to treat it, enabling medical professionals to save a life. Additionally, bacteriophages are being investigated as an alternative to antibiotics. In this therapy, viruses are used to inject bacteria with their genetic material so that the bacteria can use the machinery of their hosts to grow.

According to the Centers for Disease Control and Prevention (CDC), antibiotic-resistant bacterial infections affect approximately 33 000 people in Europe each year. Antibiotic resistance is predicted to increase globally, creating considerable demand for bacteriophages.

Market Dynamics:

Driver:

Increasing antibiotic resistance

The overuse and abuse of antibiotics in both human medicine and agriculture have serious consequences, including the rise in antibiotic resistance. Antibiotic-resistant superbugs have emerged as a result of this worrying trend, necessitating the urgent need for alternative therapies like bacteriophage therapy. Moreover, bacteriophages are naturally occurring viruses that target and destroy bacteria, making them a promising weapon against these pathogens that are drug-resistant. Researchers are investigating how to effectively target and get rid of these tough bacterial strains using phage cocktails and specially created phages.

Restraint:

Insufficient clinical data and regulatory obstacles

It is difficult to persuade regulatory agencies of the safety and effectiveness of bacteriophage therapy because there aren't many large-scale, randomized controlled trials that can provide sufficient clinical evidence. However, it may take longer to get a product approved for the market and cost more money because of the strict regulatory environment for new therapies and the requirement for extensive clinical data. While overcoming these challenges, developers must also address issues with the consistency and quality of phage preparations used in clinical trials.

Opportunity:

Investments in research and development

Innovation in bacteriophage therapy is accelerating as a result of the surge in R&D spending. Phage engineering, the creation of phage libraries, and the combination of phage therapy with other therapeutic modalities like immunotherapies or antibiotics are all topics of active research. Moreover, this dynamic environment encourages a deeper comprehension of phage biology and its clinical applications, in addition to diversifying the therapeutic toolbox.

Threat:

Regulatory issues and a lack of robust clinical data

Lack of large-scale, top-notch clinical data is one of the biggest threats to the bacteriophage therapy market. Because there have been relatively few clinical trials for bacteriophage therapy, regulatory agencies may delay approvals and raise development costs. Furthermore, regulatory agencies need strong clinical evidence to approve new therapies. It can be challenging and time-consuming for developers to navigate the regulatory environment for novel therapies.

COVID-19 Impact:

The bacteriophage therapy market has been affected in different ways by the COVID-19 pandemic. Although bacteriophages and other alternative therapies have received more attention due to the increased focus on infectious diseases and antibiotic resistance, the pandemic has also focused more resources, attention, and research efforts on COVID-19. Due to supply chain issues, bacteriophage therapy clinical trials and research were delayed, and some production interruptions happened. Despite this, the pandemic brought attention to the need for a wider range of treatment options, which may hasten the adoption of bacteriophage therapy in the post-pandemic era, particularly for persistent bacterial threats in healthcare settings and antibiotic-resistant infections.

The Urinary Tract Infections segment is expected to be the largest during the forecast period

In the market for bacteriophage therapy, the urinary tract infections (UTIs) segment commands the largest share. Each year, millions of people experience UTIs, which are among the most prevalent bacterial infections. Moreover, bacteriophage therapy has become a promising alternative due to the rise in antibiotic-resistant strains that cause UTIs. It is a compelling option for both simple and complex UTIs due to its effectiveness in targeting particular uropathogenic bacteria. Further boosting the market potential for bacteriophage-based treatments in this market are the recurrent nature of UTIs and the limitations of antibiotics in preventing relapses.

The Antimicrobial Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the market for bacteriophage therapy, antimicrobial drug discovery is growing at the highest CAGR. There has been an increase in funding and research into finding new antimicrobial agents as a result of the growing concern about antibiotic resistance around the world. The ability of bacteriophages to target and destroy bacteria that are resistant to antibiotics has attracted a lot of interest in drug discovery efforts. Furthermore, the ongoing investigation of bacteriophages potential for locating and creating novel antimicrobial remedies-solutions that are urgently required to address the mounting problem of drug-resistant infections-is the primary driver of this market's rapid growth.

Region with largest share:

The largest market share for bacteriophage therapy is anticipated to be in the North American region. A number of elements, such as a strong healthcare infrastructure, a high incidence of infections caused by bacteria resistant to antibiotics, significant investments in research and development, and a supportive regulatory environment, can be credited for this dominance. The region's thriving biotechnology and pharmaceutical sectors, along with the growing use of bacteriophage therapy in clinical settings, place North America as a market leader. Additionally, bacteriophage therapy has expanded more quickly in North America thanks to partnerships between academic institutions, pharmaceutical companies, and governmental organizations, where it now accounts for the largest market share.

Region with highest CAGR:

In the global market for bacteriophage therapy, Asia-Pacific is growing at the highest CAGR. This rapid expansion is a result of a number of factors, including the heavy prevalence of infections that are resistant to antibiotics, the expanding healthcare industry, and growing public awareness of the potential advantages of bacteriophage therapy. With a focus on creating efficient production techniques and extending clinical applications, the Asia-Pacific region is seeing significant investments in research and development. Furthermore, collaborations between local academic institutions, pharmaceutical firms from abroad, and regional biotechnology companies are promoting innovation and expanding the market.

Key players in the market:

Some of the key players in Bacteriophage Therapy market include: InnoPhage Ltd, Eliava Biopreparations Ltd., Adaptive Phage Therapeutics, Inc, Nextbiotics, Armata Pharmaceuticals Inc., Enbiotix Inc., Eligo Bioscience SA, BiomX Ltd., Phagomed Biopharma GmbH, Intodeworld Inc., Phi Therapeutics, ContraFect Corporation, Locus Biosciences Inc., Intralytix Inc., PhagePro Inc., Pherecydes Pharma and TechnoPhage SA.

Key Developments:

In May 2023, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that have exceptionally broad coverage against antibiotic resistant bacteria.

In January 2023, Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc, Armata's largest shareholder.

In July 2022, Micro biome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD). BiomX Ltd. The agreement, the second one between the two firms, uses BiomX's XMarker micro biome-based biomarker discovery platform to aid in identifying IBD-linked pathogenic bacterium. Additional agreement terms see BiomX receive research payments with Boehringer able to negotiate an exclusive right to biomarkers discovered under the collaboration.

Products Covered:

  • Phage Probiotics
  • Phage Therapeutic
  • Other Products

Types Covered:

  • Lytic
  • Lysogenic
  • Other Types

Targeted Bacterias Covered:

  • Escherichia Coli
  • Staphylococcus Aureus
  • Streptococcus
  • Pseudomonas Aeruginosa
  • Salmonella
  • Other Targeted Bacterias

Disease Indications Covered:

  • Urinary Tract Infections
  • Chronic Otitis
  • Dental Extraction
  • Chronic Ulcerative Colitis
  • Bone Infection
  • Wound and Skin Infections
  • Cystic Fibrosis
  • Other Disease Indications

Route of Administrations Covered:

  • Oral
  • Topical
  • Parenteral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Skin Infection Treatment
  • Gastroenterology
  • Wound Prophylaxis
  • Respiratory Infections Treatment
  • Urogenital Infection Treatment
  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Academic Research Organizations & Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bacteriophage Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Phage Probiotics
  • 5.3 Phage Therapeutic
  • 5.4 Other Products

6 Global Bacteriophage Therapy Market, By Type

  • 6.1 Introduction
  • 6.2 Lytic
  • 6.3 Lysogenic
  • 6.4 Other Types

7 Global Bacteriophage Therapy Market, By Targeted Bacteria

  • 7.1 Introduction
  • 7.2 Escherichia Coli
  • 7.3 Staphylococcus Aureus
  • 7.4 Streptococcus
  • 7.5 Pseudomonas Aeruginosa
  • 7.6 Salmonella
  • 7.7 Other Targeted Bacterias

8 Global Bacteriophage Therapy Market, By Disease Indication

  • 8.1 Introduction
  • 8.2 Urinary Tract Infections
  • 8.3 Chronic Otitis
  • 8.4 Dental Extraction
  • 8.5 Chronic Ulcerative Colitis
  • 8.6 Bone Infection
  • 8.7 Wound and Skin Infections
  • 8.8 Cystic Fibrosis
  • 8.9 Other Disease Indications

9 Global Bacteriophage Therapy Market, By Route of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Topical
  • 9.4 Parenteral

10 Global Bacteriophage Therapy Market, By Distribution Channel

  • 10.1 Introduction
  • 10.2 Hospital Pharmacies
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11 Global Bacteriophage Therapy Market, By Application

  • 11.1 Introduction
  • 11.2 Skin Infection Treatment
  • 11.3 Gastroenterology
  • 11.4 Wound Prophylaxis
  • 11.5 Respiratory Infections Treatment
  • 11.6 Urogenital Infection Treatment
  • 11.7 Diagnostic
  • 11.8 Antimicrobial Drug Discovery
  • 11.9 Veterinary Medicines
  • 11.10 Other Applications

12 Global Bacteriophage Therapy Market, By End User

  • 12.1 Introduction
  • 12.2 Hospitals & Clinics
  • 12.3 Academic Research Organizations & Institutes
  • 12.4 Other End Users

13 Global Bacteriophage Therapy Market, By Geography

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 US
    • 13.2.2 Canada
    • 13.2.3 Mexico
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 Italy
    • 13.3.4 France
    • 13.3.5 Spain
    • 13.3.6 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 New Zealand
    • 13.4.6 South Korea
    • 13.4.7 Rest of Asia Pacific
  • 13.5 South America
    • 13.5.1 Argentina
    • 13.5.2 Brazil
    • 13.5.3 Chile
    • 13.5.4 Rest of South America
  • 13.6 Middle East & Africa
    • 13.6.1 Saudi Arabia
    • 13.6.2 UAE
    • 13.6.3 Qatar
    • 13.6.4 South Africa
    • 13.6.5 Rest of Middle East & Africa

14 Key Developments

  • 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 14.2 Acquisitions & Mergers
  • 14.3 New Product Launch
  • 14.4 Expansions
  • 14.5 Other Key Strategies

15 Company Profiling

  • 15.1 InnoPhage Ltd
  • 15.2 Eliava Biopreparations Ltd.
  • 15.3 Adaptive Phage Therapeutics, Inc
  • 15.4 Nextbiotics
  • 15.5 Armata Pharmaceuticals Inc.
  • 15.6 Enbiotix Inc.
  • 15.7 Eligo Bioscience SA
  • 15.8 BiomX Ltd.
  • 15.9 Phagomed Biopharma GmbH
  • 15.10 Intodeworld Inc.
  • 15.11 Phi Therapeutics
  • 15.12 ContraFect Corporation
  • 15.13 Locus Biosciences Inc.
  • 15.14 Intralytix Inc.
  • 15.15 PhagePro Inc.
  • 15.16 Pherecydes Pharma
  • 15.17 TechnoPhage SA

List of Tables

  • Table 1 Global Bacteriophage Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bacteriophage Therapy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Bacteriophage Therapy Market Outlook, By Phage Probiotics (2021-2030) ($MN)
  • Table 4 Global Bacteriophage Therapy Market Outlook, By Phage Therapeutic (2021-2030) ($MN)
  • Table 5 Global Bacteriophage Therapy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Bacteriophage Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Bacteriophage Therapy Market Outlook, By Lytic (2021-2030) ($MN)
  • Table 8 Global Bacteriophage Therapy Market Outlook, By Lysogenic (2021-2030) ($MN)
  • Table 9 Global Bacteriophage Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Bacteriophage Therapy Market Outlook, By Targeted Bacteria (2021-2030) ($MN)
  • Table 11 Global Bacteriophage Therapy Market Outlook, By Escherichia Coli (2021-2030) ($MN)
  • Table 12 Global Bacteriophage Therapy Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
  • Table 13 Global Bacteriophage Therapy Market Outlook, By Streptococcus (2021-2030) ($MN)
  • Table 14 Global Bacteriophage Therapy Market Outlook, By Pseudomonas Aeruginosa (2021-2030) ($MN)
  • Table 15 Global Bacteriophage Therapy Market Outlook, By Salmonella (2021-2030) ($MN)
  • Table 16 Global Bacteriophage Therapy Market Outlook, By Other Targeted Bacterias (2021-2030) ($MN)
  • Table 17 Global Bacteriophage Therapy Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 18 Global Bacteriophage Therapy Market Outlook, By Urinary Tract Infections (2021-2030) ($MN)
  • Table 19 Global Bacteriophage Therapy Market Outlook, By Chronic Otitis (2021-2030) ($MN)
  • Table 20 Global Bacteriophage Therapy Market Outlook, By Dental Extraction (2021-2030) ($MN)
  • Table 21 Global Bacteriophage Therapy Market Outlook, By Chronic Ulcerative Colitis (2021-2030) ($MN)
  • Table 22 Global Bacteriophage Therapy Market Outlook, By Bone Infection (2021-2030) ($MN)
  • Table 23 Global Bacteriophage Therapy Market Outlook, By Wound and Skin Infections (2021-2030) ($MN)
  • Table 24 Global Bacteriophage Therapy Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 25 Global Bacteriophage Therapy Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 26 Global Bacteriophage Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 27 Global Bacteriophage Therapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 28 Global Bacteriophage Therapy Market Outlook, By Topical (2021-2030) ($MN)
  • Table 29 Global Bacteriophage Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 30 Global Bacteriophage Therapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Bacteriophage Therapy Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 Global Bacteriophage Therapy Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 Global Bacteriophage Therapy Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Bacteriophage Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 Global Bacteriophage Therapy Market Outlook, By Skin Infection Treatment (2021-2030) ($MN)
  • Table 36 Global Bacteriophage Therapy Market Outlook, By Gastroenterology (2021-2030) ($MN)
  • Table 37 Global Bacteriophage Therapy Market Outlook, By Wound Prophylaxis (2021-2030) ($MN)
  • Table 38 Global Bacteriophage Therapy Market Outlook, By Respiratory Infections Treatment (2021-2030) ($MN)
  • Table 39 Global Bacteriophage Therapy Market Outlook, By Urogenital Infection Treatment (2021-2030) ($MN)
  • Table 40 Global Bacteriophage Therapy Market Outlook, By Diagnostic (2021-2030) ($MN)
  • Table 41 Global Bacteriophage Therapy Market Outlook, By Antimicrobial Drug Discovery (2021-2030) ($MN)
  • Table 42 Global Bacteriophage Therapy Market Outlook, By Veterinary Medicines (2021-2030) ($MN)
  • Table 43 Global Bacteriophage Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 44 Global Bacteriophage Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 Global Bacteriophage Therapy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 46 Global Bacteriophage Therapy Market Outlook, By Academic Research Organizations & Institutes (2021-2030) ($MN)
  • Table 47 Global Bacteriophage Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.